Maged Shenouda, Chief Financial Officer at RELMADA THERAPEUTICS, INC. (RLMD), bought 200,000 shares at $4.20 ($844K) on 2026-09-09, disclosed to the SEC on 2026-09-11.
Chief Financial Officer Maged Shenouda purchased 120,200 shares of Relmada Therapeutics for $504,840, signaling confidence in the company's turnaround narrative. This move comes as the stock has recently dropped nearly 14% over the past month, potentially presenting a value entry point.
The stock is down 13.53% over the last 30 days and 38.4% over the last 90 days, trading at $4.09, which is 48.78% below its 52-week high of $7.985.
1) Q2 2026 Earnings Call on August 7, 2026, where management discussed manufacturing activities for NDV-01 and an IND filing target by the end of 2026. 2) The company is targeting a mid-2026 Phase 3 RESCUE registrational program for NDV-01, following positive 12-month Phase 2 data reported in Q1 2026.
The stock is currently in oversold territory with a short interest of 13.54% of the float, indicating significant bearish sentiment that could persist despite insider buying.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.20 | 120,200 | $505K | 59.8% |
| 2 | $4.25 | 79,800 | $339K | 40.2% |
| Total | $4.22 avg | 200,000 | $844K | 100% |
| Filing → |
| RLMD | BUY | 2025-05-20 | $97K | — | Filing → |
| RLMD | BUY | 2024-09-11 | $207K | — | Filing → |
| RLMD | BUY | 2024-01-31 | $126K | — | Filing → |